| Name | G antigen 13 |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Although none of the presented abstracts address GAGE13 directly, one study that profiled cancer‐testis antigens in prostate cancer identified a related family member – GAGE1 – as exhibiting elevated autoantibody titers in patient serum, suggesting that proteins within the GAGE family may be involved in tumor immunogenicity and could serve as diagnostic or immunotherapeutic biomarkers (see."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Given that GAGE proteins belong to a broader class of tumor‐associated antigens expressed in diverse malignancies, it is plausible that GAGE13 functions similarly by contributing to the display of cancer-specific epitopes that stimulate an immune response. In this context, the functional role of GAGE13 can be inferred to include participation in cellular processes that mark malignant cells for immune recognition, a feature that aligns with other oncogenic mechanisms described across these studies. For example, several of the abstracts highlight changes in gene expression and protein regulation that drive tumor cell proliferation, survival, and drug resistance through mechanisms ranging from increased expression of proliferation drivers (such as PTTG1 in multiple myeloma)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "and altered chromatin bookmarking"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "to the activation of diverse pathways associated with chemoresistance in ovarian cancer"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "and proteomic changes in response to tyrosine kinase inhibition in chronic myeloid leukemia."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": " Together, these findings support a scenario in which GAGE13 – as a member of the cancer-testis antigen family – may participate in modulating tumor immunogenicity and provide a putative link between altered antigen expression and oncogenic signaling cascades, thereby representing a potential target for diagnostic and therapeutic strategies.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Henry A Adeola, Muneerah Smith, Lisa Kaestner, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncotarget (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.18632/oncotarget.7359"}], "href": "https://doi.org/10.18632/oncotarget.7359"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26885621"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26885621"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Jacqueline E Noll, Kate Vandyke, Duncan R Hewett, et al. "}, {"type": "b", "children": [{"type": "t", "text": "PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Hematol Oncol (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/s13045-015-0209-2"}], "href": "https://doi.org/10.1186/s13045-015-0209-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26445238"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26445238"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Mansi Arora, Colin Z Packard, Tapahsama Banerjee, et al. "}, {"type": "b", "children": [{"type": "t", "text": "RING1A and BMI1 bookmark active genes via ubiquitination of chromatin-associated proteins."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nucleic Acids Res (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/nar/gkv1223"}], "href": "https://doi.org/10.1093/nar/gkv1223"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26578590"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26578590"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Cheryl A Sherman-Baust, Kevin G Becker, William H Wood Iii, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Ovarian Res (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/1757-2215-4-21"}], "href": "https://doi.org/10.1186/1757-2215-4-21"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22141344"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22141344"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Proteomes (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3390/proteomes2030363"}], "href": "https://doi.org/10.3390/proteomes2030363"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28250386"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28250386"}]}]}]}
|
| Synonyms | GAGE12A, GAGE-13, GAGE-12A |
| Proteins | GAG13_HUMAN |
| NCBI Gene ID | 645051 |
| API | |
| Download Associations | |
| Predicted Functions |
![]() |
| Co-expressed Genes |
![]() |
| Expression in Tissues and Cell Lines |
![]() |
GAGE13 has 400 functional associations with biological entities spanning 6 categories (molecular profile, disease, phenotype or trait, functional term, phrase or reference, chemical, cell line, cell type or tissue, gene, protein or microRNA) extracted from 22 datasets.
Click the + buttons to view associations for GAGE13 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| CCLE Cell Line Gene CNV Profiles | cell lines with high or low copy number of GAGE13 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset. | |
| ChEA Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of GAGE13 gene from the CHEA Transcription Factor Binding Site Profiles dataset. | |
| ChEA Transcription Factor Targets | transcription factors binding the promoter of GAGE13 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset. | |
| ChEA Transcription Factor Targets 2022 | transcription factors binding the promoter of GAGE13 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset. | |
| CM4AI KOLF21J CRISPRi Gene Perturbation Atlas | gene perturbations changing expression of GAGE13 gene from the CM4AI KOLF21J CRISPRi Gene Perturbation Atlas dataset. | |
| COSMIC Cell Line Gene CNV Profiles | cell lines with high or low copy number of GAGE13 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores 2025 | diseases co-occuring with GAGE13 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| ENCODE Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of GAGE13 gene from the ENCODE Transcription Factor Binding Site Profiles dataset. | |
| ENCODE Transcription Factor Targets | transcription factors binding the promoter of GAGE13 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset. | |
| Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles | cell lines with high or low expression of GAGE13 gene relative to other cell lines from the Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles dataset. | |
| HPA Cell Line Gene Expression Profiles | cell lines with high or low expression of GAGE13 gene relative to other cell lines from the HPA Cell Line Gene Expression Profiles dataset. | |
| HPA Tissue Protein Expression Profiles | tissues with high or low expression of GAGE13 protein relative to other tissues from the HPA Tissue Protein Expression Profiles dataset. | |
| JASPAR Predicted Human Transcription Factor Targets 2025 | transcription factors regulating expression of GAGE13 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Human Transcription Factor Targets dataset. | |
| JASPAR Predicted Transcription Factor Targets | transcription factors regulating expression of GAGE13 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles | cell lines with high or low copy number of GAGE13 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset. | |
| LOCATE Predicted Protein Localization Annotations | cellular components predicted to contain GAGE13 protein from the LOCATE Predicted Protein Localization Annotations dataset. | |
| Rummagene Transcription Factor Associations 2026 | transcription factors regulating expression of GAGE13 gene from the Rummagene Transcription Factor Associations 2026 dataset. | |
| RummaGEO Drug Perturbation Signatures | drug perturbations changing expression of GAGE13 gene from the RummaGEO Drug Perturbation Signatures dataset. | |
| RummaGEO Gene Perturbation Signatures | gene perturbations changing expression of GAGE13 gene from the RummaGEO Gene Perturbation Signatures dataset. | |
| TargetScan Predicted Nonconserved microRNA Targets | microRNAs regulating expression of GAGE13 gene predicted using nonconserved miRNA seed sequences from the TargetScan Predicted Nonconserved microRNA Targets dataset. | |
| TCGA Signatures of Differentially Expressed Genes for Tumors | tissue samples with high or low expression of GAGE13 gene relative to other tissue samples from the TCGA Signatures of Differentially Expressed Genes for Tumors dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 | tissues co-occuring with GAGE13 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset. | |